Patents Assigned to Institut Pasteur
  • Patent number: 11815513
    Abstract: The invention relates to the diagnosis of a SARS-associated coronavirus, such as a SARS CoV-2 infection and SARS-CoV infection, using the SARS-CoV and SARS-CoV-2 nucleocapsid proteins and antibodies binding to these proteins. The invention encompasses reagents, methods and kits for the detection of a SARS-associated coronavirus.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: November 14, 2023
    Assignee: INSTITUT PASTEUR
    Inventors: Sylvie Van Der Werf, Nicolas Escriou, Caroline Demeret, Stéphane Petres, Pierre Lafaye, Jacques Bellalou
  • Publication number: 20230346728
    Abstract: A method of treating obesity, preventing weight gain, reducing the rate of weight gain, and treating adverse effects related to obesity by administering SANA to induce thermogenesis in a subject.
    Type: Application
    Filed: March 29, 2023
    Publication date: November 2, 2023
    Applicants: Institut Pasteur de Montevideo, Universidad de la República
    Inventors: Carlos Batthyány, Gloria Virginia López, Carlos Escande, Jorge Rodriguez Duarte, Williams Arturo Porcal Quinta, Rosina Dapueto Capuccio, Gérman Adrian Galliussi López, Mária Pia Garat Nuñez
  • Patent number: 11795515
    Abstract: Methods, primers, sets of primers, probes, compositions, and kits for detecting presence or absence of SARS-CoV-2 in a sample are provided.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: October 24, 2023
    Assignee: INSTITUT PASTEUR
    Inventors: Flora Donati, Mélanie Albert, Sylvie Behillil, Vincent Enouf, Sylvie van der Werf
  • Patent number: 11780934
    Abstract: It has been discovered that disrupting the stromal capsule restores a better vasculature/tumor perfusion and improve T cells infiltration inside the core of a melanoma. The invention relates to the use of drugs or immunoconjugates that target the transmembrane protease ADAM12 and deplete the cells that express it. Since ADAM12 protein is specifically expressed by stromal cells of the tumor stromal capsule and around vessels in models for prostate cancer, neuroendocrine pancreatic cancer and melanoma, an ADAM12 inhibitor is useful in anti-tumor therapies as an adjuvant. The invention encompasses methods, compositions, and kits containing ADAM12 inhibitors for use in the depletion of ADAM12+ stromal cells in cancer patient, particularly together with anti-tumor compounds and treatments.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: October 10, 2023
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Lucie Peduto, Selene Di Carlo
  • Patent number: 11779640
    Abstract: The present invention relates to a lentiviral vector-based Japanese encephalitis (JE) immunogenic composition. The present invention is directed to a recombinant lentiviral vector expressing the precursor of membrane (prM) and the envelope (E) protein, in particular glycoprotein of a Japanese encephalitis virus (JEV) or immunogenic fragments thereof. The present invention also provides cells expressing the lentiviral vector, uses and methods to prevent a JEV infection in a mammalian host, especially in a human or an animal host, in particular a pig or a piglet, preferably a domestic pig or a domestic piglet.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: October 10, 2023
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Pierre Charneau, Philippe Despres, Melissanne De Wispelaere, Philippe Souque, Marie-Pascale Frenkiel
  • Patent number: 11759516
    Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
    Type: Grant
    Filed: August 11, 2022
    Date of Patent: September 19, 2023
    Assignee: INSTITUT PASTEUR
    Inventors: Etienne Simon-Loriere, Matthieu Prot, Xavier Montagutelli
  • Patent number: 11730813
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that potently neutralize infection of both RABV and non-RABV lyssaviruses. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of RABV infection and infection with non-RABV lyssaviruses.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: August 22, 2023
    Assignees: HUMABS BIOMED SA, INSTITUT PASTEUR
    Inventors: Davide Corti, Hervé Bourhy
  • Patent number: 11732312
    Abstract: K13-propeller polymorphism is a useful molecular marker for tracking the emergence and spread of ART-resistant P. falciparum. The invention encompasses methods, compositions, and kits for detecting and genotyping Plasmodium, for example, Plasmodium falciparum. The methods, compositions, and kits can be used to detect the presence or absence of a mutated K-13 propeller nucleic acid or protein in the sample.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: August 22, 2023
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT PASTEUR DU CAMBODGE
    Inventors: Frederic Ariey, Odile Puijalon, Didier Menard, Francoise Benoit-Vical, Johann Beghain, Benoit Witkowski, Jean-Christophe Barale, Christiane Bouchier, Nimol Khim
  • Patent number: 11725183
    Abstract: The present invention relates to an in vitro method of culturing a segmented filamentous bacterium strain, comprising co-culturing said segmented filamentous bacterium strain with a eukaryotic host cell, wherein the culture is performed at an O2 level inferior to 5% in a rich tissue culture liquid medium containing bacterial medium components including iron. The present invention also relates to methods for genetically modifying a segmented filamentous bacterium strain comprising a step a culturing the strain in vitro.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: August 15, 2023
    Assignees: INSTITUT PASTEUR, FONDATION IMAGINE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE PARIS CITE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Gerard Eberl, David Bikard, Pamela Schnupf, Nadine Cerf Bensussan, Valerie Gaboriau-Routhiau, Philippe Sansonetti
  • Patent number: 11723977
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that potently neutralize infection of both RABV and non-RABV lyssaviruses. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of RABV infection and infection with non-RABV lyssaviruses.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: August 15, 2023
    Assignees: Institut Pasteur, Humabs Biomed SA
    Inventors: Davide Corti, Hervé Bourhy
  • Patent number: 11723968
    Abstract: The present invention describes specific engineering of the hantavirus spike proteins with modifications to stabilize (Gn/Gc)n heterodimer contacts and/or Gc homodimer contacts and/or Gn/Gn oligomer contacts on the spike with the purpose of using them as immunogens in next-generation vaccine design. Said spike proteins have been covalently stabilized by at least one disulphide inter-chain bond between Gn/Gc heterodimers and/or between Gc homodimers and/or between Gn homo-oligomers as they are presented at the surface of infectious virions. It also involves spike stabilization by introduction of cavity-filling amino acids with a bulky side chain at the above-mentioned contacts.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 15, 2023
    Assignees: FUNDACION CIENCIA PARA LA VIDA, INSTITUT PASTEUR
    Inventors: Nicole Tischler, Eduardo Andrés Bignon Silva, Félix Augusto Rey, Pablo Guardado Calvo
  • Publication number: 20230237651
    Abstract: A method for generating a color-faithful extended-depth-of-field (EDF) image from a color volume of 2D images acquired at different focal depths using a microscope.
    Type: Application
    Filed: June 4, 2021
    Publication date: July 27, 2023
    Applicants: VITADX INTERNATIONAL, INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Alexandre BOUYSSOUX, Riadh FEZZANI, Jean-Christophe OLIVO-MARIN
  • Patent number: 11679140
    Abstract: The present invention relates to the use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin for modulating cellular redox homeostasis. A particularly preferred use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin in the context of the present invention is as an antioxidant. The present invention also concerns a virally-mediated gene therapy for restoring genetically-impaired auditory and vestibular functions in subjects suffering from an Usher syndrome. More precisely, this gene therapy takes advantage of an AAV2/8 vector expressing at least one USH1 gene product, preferably SANS.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: June 20, 2023
    Assignees: INSTITUT PASTEUR, Centre National de la Recherche Scientifique (CNRS), Universite Clermont Auvergne, Sorbonne Universite
    Inventors: Christine Petit, Paul Avan, Sedigheh Delmaghani, Jean Defourny, Asadollah Aghaie, Saaid Safieddine, Alice Emptoz
  • Patent number: 11680245
    Abstract: Innate lymphoid cells (ILCs) represent innate versions of T helper and cytotoxic T cells that differentiate from committed ILC precursors (ILCP). Still, how ILCP relate to mature tissue-resident ILCs remains unclear. ILCP that are present in the blood and all tested lymphoid and non-lymphoid human tissues were identified. Human ILCP fail to express the signature transcription factors (TF) and cytokine outputs of mature NK cells and ILCs but are epigenetically poised to do so. Human ILCP robustly generate all ILC subsets in vitro and in vivo. While human ILCP express RAR related orphan receptor C (RORC), circulating ILCP can be found in RORC-deficient patients that retain potential for EOMES+ NK cells, T-BET+ ILC1, GATA-3+ ILC2 and for IL-22+ but not for IL-17A+ ILC3. A model of tissue ILC differentiation (‘ILC-poiesis’) is proposed whereby diverse ILC subsets are generated in situ from ILCP in response to environmental stressors, inflammation and infection.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: June 20, 2023
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: James Di Santo, Ai Ing Lim
  • Patent number: 11676247
    Abstract: The invention relates to reconstructing a synthetic dense super-resolution image from at least one low-information-content image, for example from a sequence of diffraction-limited images acquired by single molecule localization microscopy. After having obtained such a sequence of diffraction-limited images, a sparse localization image is reconstructed from the obtained sequence of diffraction-limited images according to single molecule localization microscopy image processing.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: June 13, 2023
    Assignee: INSTITUT PASTEUR
    Inventors: Christophe Zimmer, Wei Ouyang
  • Publication number: 20230157994
    Abstract: A method of treating COVID-19 in a patient. The patient may be in moderate to advanced stages of COVID-19 infection. The method includes administering to the patient a therapeutically effective amount of at least one antagonist or inhibitor of chemokine receptor CXCR4. The at least one antagonist or inhibitor of chemokine receptor CXCR4 is distinct from hydroxychloroquine.
    Type: Application
    Filed: May 5, 2021
    Publication date: May 25, 2023
    Applicants: 4LIVING BIOTECH, UNIVERSITE DE BORDEAUX, CENTRE HOSPITALIER DE BORDEAUX, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM, INSTITUT PASTEUR DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE LILLE
    Inventors: Patrick BERGER, Isabelle DUPIN, Renaud PREVEL, Chloé JAMES, Pierre-Olivier GIRODET, Keren BISMUTH, Revital RATTENBACH, Jérôme BRETON, Francois TROTTEIN, Valentin SENCIO
  • Patent number: 11642404
    Abstract: A method of generating an antibody and cellular immune response against a Plasmodium in a primate, comprising administering at least 103 genetically modified live Plasmodium to the primate, wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein, to thereby induce an antibody and cellular immune response against the Plasmodium in the primate. In some embodiments at least 104 genetically modified live Plasmodium is administered to the primate.
    Type: Grant
    Filed: January 18, 2021
    Date of Patent: May 9, 2023
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Salah Mecheri, Robert Menard, Claudia Demarta-Gatsi
  • Patent number: 11643625
    Abstract: The present invention relates generally to an organ-on-chip microfluidic device (10) comprising a first element (11), a second element (16), and a hydrogel layer (14) which is interposed between the first element and the second element. The shapes and dimensions of the first element, the second element, and the hydrogel layer are determined to enable the hydrogel layer to expand and retract in a given direction in the conditions of use disclosed herein, in particular to mimic organ functions in vitro. The present invention further relates to method of producing the microfluidic device and to application of said microfluidic device in biomedical field, especially for mimicking the architecture and function of organs.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: May 9, 2023
    Assignee: INSTITUT PASTEUR
    Inventor: Samy Olivier Gobaa
  • Patent number: 11638751
    Abstract: A recombinant attenuated Mopeia virus (MOPV) comprising a recombinant genomic S segment that encodes a nucleoprotein having attenuated exonuclease activity, and optionally further encodes a non-MOPV arenavirus glycoprotein. Use of the recombinant attenuated MOPV to induce an immune response in a subject.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: May 2, 2023
    Assignee: INSTITUT PASTEUR
    Inventors: Sylvain Baize, Audrey Page, Xavier Carnec, Mathieu Jean Simon Mateo, Stephanie Reynard, Alexandra Fizet
  • Publication number: 20230130605
    Abstract: The invention relates to mutant DNA polymerases of the Pol theta subfamily capable of performing non-templated nucleic acid extension, or of a functional fragment of such a polymerase, methods of producing these mutant DNA polymerases, kits and methods of using these mutant DNA polymerases.
    Type: Application
    Filed: June 24, 2022
    Publication date: April 27, 2023
    Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Marc DELARUE, Volahasina (Irina) RANDRIANJATOVO GBALOU